Background: Curative intent chemotherapy for acute myelogenous leukemia (AML) leads to prolonged severe neutropenia, during which patients are highly susceptible to infection. Traditionally these high-risk patients were treated as inpatients. Our center recently implemented a selective ambulatory management policy for AML patients undergoing chemotherapy.
introduction
Curative intent chemotherapy for acute myelogenous leukemia (AML) leads to prolonged severe neutropenia, during which patients are highly susceptible to infection. Traditionally these patients have been hospitalized for the duration of the chemotherapy until count recovery. An increasing number of institutions are implementing selective early discharge and outpatient protocols of intensive chemotherapy in response to limited health care resources and to increase patient comfort. Ambulatory care has regularly been described in solid tumours, high-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation (HSCT) and more recently in the allogeneic nonmyeloablative HSCT setting, despite earlier studies of protective isolation indicating an infection preventative benefit [1] [2] [3] . A small number of studies have reported outpatient management of select patients with AML [4] [5] [6] [7] [8] . These investigations have documented the feasibility of outpatient management in high-risk neutropenic AML patients [9, 10] . The principal concerns with ambulatory care are the reduced surveillance of patients for febrile neutropenia and bleeding, and the possible delay in medical intervention, which could compromise the safety of patients.
Building on our previous experience with the outpatient management of AML patients treated with curative intent chemotherapy [11] , we conducted a retrospective study of the incidence of septicemia in AML patients over a 5 years period. The time period of the review included before and after a change in policy from primarily inpatient management to selective outpatient management coupled with prophylactic antibiotic therapy, to allow a comparative retrospective analysis of both treatment periods and safety assessment. 
population
The population of interest met the following inclusion criteria: all adult AML patients treated by the L/BMT program of BC from February 1999 to February 2004 with curative intent chemotherapy for de novo, secondary AML, and treatment-related AML. Some patients have been already described in a previous report [11] . Exclusion criteria removed AML patients not treated with the standard induction or consolidation chemotherapy regimen from the study, and patients treated with palliative intent. Salvage cycles of intensified chemotherapy such as VP16-cyclophosphamide or cyclophosphamide-carboplatin given for refractory or relapsed AML were also excluded, as those are never done as outpatient in our centre. All patients signed informed consent.
treatment protocol
A variety of chemotherapy regimens were administered and are described in Table 1 . Chemotherapy regimens were classified as 7 + 3 or similar (group 7 + 3), or as high-dose cytarabine-containing regimens (group HIDAC). In our institution, patients <60 years of age were preferentially treated with HIDAC. Historically, patients have been hospitalized for the duration of chemotherapy and until count recovery. Since September 2001, our institution has implemented a selective ambulatory protocol, which allows the majority of consolidation cycles to be administered entirely as outpatient. In addition, some select patients receiving induction cycles are discharged early from the inpatient ward. Inpatient cycle (IptC) implied that patients received chemotherapy and supportive care as inpatients, and left the hospital after day+15 after chemotherapy, or after absolute neutrophil count (ANC) ‡0.5 · 10 9 /l. Outpatient cycle (OptC) implied ambulatory administration of chemotherapy and supportive care. Early discharge cycle (EdcC) implied that patients received chemotherapy as inpatients, but left the hospital before day+15 after chemotherapy or before ANC ‡0. [12] . Febrile neutropenic patients were reevaluated daily to determine their eligibility for continued ambulatory treatment based. The criteria for admission of patients with neutropenic fever included hemodynamic instability (hypotension unresponsive to fluid challenge or marked tachycardia), hypoxia (O 2 saturation <92% on room air), a temperature >39.5°C, fever unresponsive to therapy with antibiotics for 3 days, rigors, World Health Organization grade 3 bleeding, requirement of i.v. antibiotics more than o.d., neutropenic colitis, failure to thrive as an outpatient or if the caregiver was unable to adequately care for the patient. AML neutropenic patients who were requiring admission to the hospital were admitted on the same day or night. Direct admissions to the L/BMT unit were requested in priorities. If this was not possible, off-service bed or emergency room admission were done. The L/BMT attending were responsible for the offservice AML patients.
microbial samples and definitions
Blood samples for culture were drawn from indwelling catheters upon presentation with an oral temperature of 38.0°C on two or more occasions over a 12 h period, a single oral temperature of 38.3°C, or hemodynamic instability. Subsequent cultures were obtained 2-3 times a week in the event of prolonged febrile episodes. Each set consisted of an aerobic and anaerobic bottle with 10 ml blood in each, incubated at 35.0°C in the BACTEC 9240 continuous monitor system (Becton, Dickinson and Company, Franklin Lakes, NJ). Aspartate aminotransferase was carried out according to Clinical and Laboratory Institute (formerly National Committee on Clinical Laboratory Standards) using either disk diffusion 
statistical methods
The primary outcome was the development of clinically significant positive blood cultures (septicemia). Stratification was carried out according to the type of cycle (induction or consolidation), chemotherapy regimen (group 7 + 3 versus group HIDAC), and IptC versus OptC and EdcC. All data were analyzed using the SPSSÒ statistical software package (SPSS, Inc., Chicago, IL). Student unpaired t-tests, Fisher's exact tests, and chi-square tests were used for univariated analysis. Logistic regression was used to carry out multivariate analysis. Results were considered significant at P £ 0.05 (two-tailed for all tests).
results patients characteristics
From February 1999 to February 2004, a total of 623 cycles of chemotherapy that met our inclusion criteria were administered to 294 patients, with a mean of 2.1 cycles per patient (range 1-8) ( Table 2 ). In all, 332 cycles of the group 7 + 3 chemotherapy regimen and 291 cycles of the group HIDAC chemotherapy regimen were administered. Chemotherapy sequence data indicated that 328 cycles were given as induction chemotherapy, which includes reinductions with conventional chemotherapy (no intensification) after failed induction cycles or relapses; 295 cycles were given as consolidation chemotherapy. When comparing patient discharge status, we observed that 426 cycles were spent entirely as inpatient (IptC); 157 cycles were spent entirely as outpatient (OptC) and 40 cycles as early discharge (EdcC) ( Table 3) .
septicemia
One hundred and twenty-six episodes of microbiologically defined septicemia were recorded in the 623 cycles of chemotherapy (20%), of which 21 episodes yielded >1 identified organism. All polymicrobial episodes occurred in different patients. Age of patients with septicemia was 48.4 versus 53.5 years old for patients without septicemia (P = 0.01). When stratified by chemotherapy sequence, we noted an increase in septicemia incidence from 17% (55/328) for induction cycle chemotherapy to 24% (71/295) for consolidation cycle chemotherapy (P £ 0.05). Percent occurrence of septicemia stratified by chemotherapy regimen indicated 17% (57/332) for group 7 + 3 and 24% (69/291) for group HIDAC (P £ 0.05).
ambulatory program
The incidences of septicemia episodes when stratified by discharge status were 22%, 13%, and 28% for IptC, OptC, and EdcC, respectively (P £ 0.05) ( Table 4 ). During OptC, there were 27 admissions (17%) before day+30 of chemotherapy. Two patients were admitted to continue chemotherapy (day+1 and day+2) as inpatient which was considered to be more appropriate for them and one patient progressed with AML during treatment was admitted on day+8 for salvage chemotherapy. Twenty-four outpatients were admitted on day+16 (range day+1 to day+21) for complication: 12 for sepsis, six for neutropenic fever, three for pneumonia [one aspergillosis, two not otherwise specified (NOS)], one for cerebellar toxicity, one for pain investigation, and one for blood culture/resistance patterns A total of 152 clinically significant isolates were found, grouped as 55% Gram-positive bacteria, 39% Gram-negative bacteria, 4% fungal organisms, and 2% NOS (Table 5 ). Coagulasenegative Staphylococci and S. viridans were the most frequently isolated pathogens recovered in 22% and 18% of cases, respectively. This was followed by Escherichia coli in 11% and Klebsiella spp. in 8%. A significant decrease in incidence of Gram-negative septicemia occurred in ambulatory care patients (with ciprofloxacin prophylaxis) compared with inpatients (without ciprofloxacin prophylaxis) from 46% to 36% of bloodstream infections (P £ 0.05). Resistance to ciprofloxacin was seen in 25% of E. coli. We encountered 14 episodes of E. coli septicemia during InptC and two episodes of E. coli septicemia during OptC. Fourteen percent (2/14) of the IptC isolates displayed ciprofloxacin resistance, compared with 2/2 of the OptC E. coli isolates. In addition, two methicillin resistant Staphylococcus aureus were isolated, and no vancomycin resistance was encountered in any isolates.
uni/multivariate analysis
Univariate analysis identified the chemotherapy regimen (group HIDAC), as well as the chemotherapy cycle (consolidation) as a significant factor (P £ 0.05) for higher risk of septicemia incidence. Multivariate analysis identified chemotherapy regimen (group HIDAC) as a significant determining factor in the occurrence of septicemia. discussion Ambulatory management of neutropenic AML patients with curative intent chemotherapy is gradually increasing in acceptance. Investigations currently published differ in patient selection, treatment design, and methodology; however, the main objectives of these investigations are similar in nature and focus on the safety and feasibility of ambulatory care [4] [5] [6] [7] [8] . This retrospective study was designed to evaluate the incidence and microbial etiology of septicemia following the implementation of an ambulatory policy for AML patients. It also allowed us to elucidate some of the risk factors for septicemia and confirmed feasibility and safety.
To observe any trends in infection due to the implementation of the new ambulatory policy, the study period included 2.5 years before and following the change in policy from primarily inpatient management to selective ambulatory management with prophylactic antibiotic therapy. Our results appear to indicate that with our current discharge guidelines and antimicrobial prophylaxis a decrease in septicemia is attainable, which translates into a feasible ambulatory policy. We recognize that patient bias was inevitable by choosing for ambulatory care only patients with favorable performance status.
Multivariate statistical analysis of septicemia incidence implicated the HIDAC chemotherapy regimen as a significant HIDAC, high-dose cytarabine-containing regimen; IpT, inpatient; OpT, outpatient; EdC, early discharge patient; IND, induction chemotherapy; CON, consolidation chemotherapy.
Annals of Oncology original article risk factor. Stratification of septicemia incidence by chemotherapy regimen reflects this finding, indicating an increase in septicemia from 17% for group 7 + 3 to 24% for group HIDAC chemotherapy. Destruction of oral and gastrointestinal mucosa during intensive chemotherapy is closely associated with infection; therefore, these results were anticipated and are consistent with an increase in mucosal toxicity and prolonged neutropenia due to high-dose cytarabine [14] [15] [16] [17] [18] . Also of interest is the stratification of septicemia incidence by chemotherapy cycle, which shows an increase from 17% for induction to 24% for consolidation cycles. This uncharacteristic trend defied our expectations that we would anticipate higher incidence of septicemia during induction cycles due to more frequent poor performance status and comorbidities in patients at the time of diagnosis. Careful review of our data indicated that septicemia during inpatient consolidation (without antibiotic prophylaxis) is most responsible for this unexpected finding. The use of antibiotic prophylaxis in neutropenic patients has been controversial for many years. Antibiotic prophylaxis has frequently been cited as a driving force in the emergence of resistant strains. Of major concern is the reported increase in fluoroquinolone resistant strains of E. coli [19, 20] . Until recently, clinicians were faced with the dilemma of choosing between Gram-negative prophylaxis in high-risk neutropenic AML patients, which has been shown to reduce infectious complications but without a major impact on infection-related mortality or diminish the emergence of antibiotic resistance by withholding prophylactic antibiotherapy. The Infectious Diseases Society of America guidelines published in 2002 permit fluoroquinolone prophylaxis in high-risk, profoundly neutropenic patients [12] . Last year, the benefits of prophylactic antibiotics have been emphasized by two major double-blind, placebo controlled trials with levofloxacin which confirmed very significant reductions in all infection-related events (febrile episode, positive culture, bacteremias infections with Gram-negative bacilli). Bucaneve et al. [21] target 760 high-risk adults with therapy for leukemia or an autologous HSCT while Cullen et al. [22] randomized patients with solid tumor or lymphoma. Mortality was lower in the levofloxacine groups but both studies were not powered to prove a difference in mortality. A meta-analysis comparing prophylactic antibiotic therapy with placebo, confirmed a survival advantage (infection-related death and all cause mortality) and this is greatest with the use of fluoroquinolone [23] . It was recently updated to include Bucavene and Cullen studies. Among acute leukemia and HSCT patients the relative risk of death with quinolone prophylaxis was 0.587 (0.40-0.84) [24] . Nevertheless, vigilance is required to detect epidemiological shifts in pathogens and their susceptibility patterns to current prophylactic and empiric therapy. Taking into account these new evidences and the severe immunocompromised state of AML chemotherapy patients, our institution will continue to utilize fluoroquinolone prophylaxis in the ambulatory original article Annals of Oncology subgroup to prevent life-threatening Gram-negative sepsis and is considering universal bacterial prophylaxis for all AML. Over the past decade, the spectrum of pathogens that cause infections in neutropenic patients has shifted from Gramnegative bacilli to Gram-positive microorganisms possibly attributable to the increased use of prophylaxis that targets Gram-negative bacteria, intensified chemotherapy protocol, and the use of indwelling venous catheters [25, 26] . Our experience corroborates the shift in the bacterial spectrum following the implementation of selective ambulatory care with antibiotic prophylaxis targeting Gram-negative organisms.
Although our dataset on ciprofloxacin resistance in E. coli is insufficient for statistical analysis over the study period, we do report a nonsignificant increasing trend in ciprofloxacin resistance (1/9 before September 1st 2001, 3/7 after September 1st 2001). This coincides with a similar hospital wide trend of decreasing ciprofloxacin susceptibility in E. coli from 92% in 1999 to 69% in 2004 (Vancouver General Hospital internal data). Notably, in the wake of reported emergence of vancomycin resistance [27] , no resistance was observed in Enterococci spp. or other bacteria despite its use as front line empiric antibiotherapy.
conclusion
The obtained data has led us to make several important observations. First of all, we observe a decrease in septicemia in the consolidation subgroup of curative intent chemotherapy recipients postimplementation of selective discharge protocol; this shift can be correlated with a significant decrease in septicemia in the ambulatory population, leading us to conclude that the selective ambulatory management of AML chemotherapy recipients in our patient population is feasible with respect to bloodstream infections. Secondly, a notable decrease in the Gram-negative pathogens causing septicemia is experienced in the Outpatient population. We speculate that this shift is mainly due to the Gram-negative targeting ciprofloxacin antibiotic prophylaxis administered to the ambulatory population. While this practice is not advantageous in all situations due to the possible selection for antibiotic resistance, given the severe immunocompromised state of this patient group, we feel that ciprofloxacin prophylaxis is warranted.
A comprehensive ambulatory management program specifically dedicated to high-risk AML proved to be feasible and safe.
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